GlassScriptPhysician profile
Ryan Kent Meacham
NPI 1285877316
$1,689.11
in general payments reported to CMS, 2019-2025
21 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $134 · 2021: $185 · 2022: $203 · 2023: $146 · 2024: $479 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $386.99 | 2020-2025 | |
| Glaxosmithkline, LLC. | $196.35 | 2021-2025 | Nucala |
| Optinose US, INC. | $164.93 | 2019-2024 | |
| Aerin Medical INC. | $140.01 | 2020-2025 | |
| Intersect Ent, INC. | $135.26 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $100.20 | 2020-2025 | Dupixent |
| Depuy Synthes Sales INC. | $81.12 | 2022 | |
| Inspire Medical Systems, INC. | $79.84 | 2024-2025 | Inspire |
| Amgen INC. | $74.04 | 2024-2025 | Tavneos |
| Medtronic, INC. | $68.98 | 2024-2025 | Propel, Stealthstation S8 Platform |
| Innovation Technologies INC | $43.21 | 2025 | Irrisept |
| Merck Sharp & Dohme LLC | $40.51 | 2023-2025 | Keytruda |
| Stryker Corporation | $40.40 | 2019-2021 | |
| Acclarent, INC | $26.12 | 2019 | |
| Baxter Healthcare | $21.29 | 2024 | Floseal |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $18.13 | 2024 | |
| Phadia US INC. | $17.33 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.24 | 2024 | Voquezna |
| Kaleo, INC. | $13.26 | 2023 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $12.98 | 2021 | |
| Smith+Nephew, INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Meacham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.